Does HIP Cover Wegovy? Cardiovascular Exception and Alternatives

The Healthy Indiana Plan does not cover Wegovy when it is prescribed for weight loss. Indiana Medicaid’s rules exclude “anorectics or any agent used to promote weight loss” from covered drugs, and that exclusion runs through all three HIP managed care organizations: MHS, Anthem, and CareSource.¹ There is one narrow way in: HIP will consider Wegovy for members who meet strict criteria for cardiovascular risk reduction, not for weight management itself.²

Why Weight-Loss Coverage Is Off the Table

Federal law leaves anti-obesity drugs as an optional Medicaid benefit, and Indiana has chosen not to add it.³ The Indiana Health Coverage Programs regulation (405 IAC 5-24) covers FDA-approved prescription drugs except for a defined list of excluded categories, and weight-loss agents sit in that list.⁴

Each HIP plan carries this through. MHS lists “drugs for weight loss” as not covered in its pharmacy FAQ, and its Preferred Drug List excludes weight-loss drugs apart from a limited exception for orlistat.⁵⁶ CareSource’s Indiana Medicaid formulary, effective April 2026, does not list Wegovy.⁷ Anthem’s Indiana HIP prior authorization criteria for GLP-1 drugs cover Ozempic and Rybelsus for type 2 diabetes and omit Wegovy entirely.⁸

The Cardiovascular Risk Reduction Exception

Indiana Medicaid’s prior authorization document says Wegovy is “not covered exclusively for weight loss” but can be authorized for members with established cardiovascular disease who are overweight or obese and need to lower their risk of heart attack, stroke, or cardiovascular death.²

To qualify for an initial one-year authorization, a member must meet every one of these requirements:

Age 45 or older.
BMI of at least 27 kg/m², documented in chart notes from the prior three months.
Documentation within the past year of at least one of the following: prior heart attack, prior stroke (ischemic or hemorrhagic), or symptomatic peripheral arterial disease shown by amputation, revascularization, or intermittent claudication with a resting ankle-brachial index below 0.85.
Current use of appropriate cardiac medications (beta-blockers or renin-angiotensin system inhibitors along with lipid-lowering drugs), or a prescriber explanation of why those are inappropriate.
No type 1 or type 2 diabetes diagnosis.
Prescriber attestation that the member will use Wegovy alongside a reduced-calorie diet and increased physical activity.
No concurrent use of Ozempic or any other semaglutide or GLP-1 receptor agonist product.
A dose limit of 2.4 mg per week.²

The bar is high on purpose. This pathway is aimed at older adults with serious heart disease, not at HIP members whose primary goal is weight management. One more limit worth noting: although Wegovy now carries an FDA-approved indication for MASH (metabolic dysfunction-associated steatohepatitis), Indiana’s criteria for Wegovy do not include MASH as an approved use, even though Ozempic and Victoza have that pathway.²

Other GLP-1 and Weight-Loss Drugs Under HIP

The categorical exclusion sweeps in the other common options too, though there are a couple of non-weight-loss pathways worth knowing about.

Saxenda, Contrave, Qsymia, and phentermine do not appear in Indiana Medicaid’s GLP-1 prior authorization criteria, and the broad exclusion of drugs used to promote weight loss applies to all of them.⁴
Zepbound (tirzepatide) is also “not covered exclusively for weight loss,” but it can be authorized for members age 18 and older who have moderate to severe obstructive sleep apnea plus obesity, provided they meet criteria that include a BMI of at least 30, a documented apnea-hypopnea index of 15 or more, and no diabetes diagnosis. CareSource’s 2026 formulary lists Zepbound as a Tier 2 drug with prior authorization.²⁷
Ozempic and Victoza are covered for type 2 diabetes and for MASH or MASLD (fatty liver disease), but not for weight management.⁸

If Your Prescription Is Denied

HIP members have the right to appeal a pharmacy denial through their managed care plan’s internal process. Appeals are submitted in writing, the plan will send a notice explaining the denial and your appeal rights, and there is no cost to file.⁹ Because the weight-loss exclusion is categorical rather than a case-by-case clinical judgment, an appeal has the best chance when the prescriber can reframe the request around a covered indication (such as cardiovascular risk reduction) and submit documentation showing the member meets every required criterion.

Paying Out of Pocket

Novo Nordisk has introduced reduced self-pay pricing for Wegovy. The 1.5 mg and 4 mg injection doses are available at $149 per month through August 31, 2026. New patients can access an introductory offer of $199 per month for the first two months on lower doses, followed by $349 per month. Without any discount, the list price is roughly $1,349 for a 28-day supply.¹⁰

Patient Assistance Programs

Novo Nordisk runs a Patient Assistance Program for uninsured patients, but it excludes anyone enrolled in or eligible for Medicaid. A Medicaid-eligible person would need proof of a Medicaid coverage denial before being considered.¹¹ Commercial copay savings cards from the manufacturer are likewise unavailable to people on government insurance.

Could Indiana Start Covering Wegovy for Obesity?

Not soon, based on the current record. CMS proposed a rule (CMS-4208-P) that would have required state Medicaid programs to cover anti-obesity medications, but the Trump administration did not finalize that provision in the Contract Year 2026 final rule, calling it “not appropriate at this time.”¹²

A separate voluntary demonstration, called BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health), would expand Medicaid coverage of GLP-1 drugs for obesity in participating states starting May 1, 2026, with a state application deadline of July 31, 2026, and a program end of December 2031.¹³ Whether Indiana signs on is unknown. At the state level, Indiana House Bill 1202, “Medicaid coverage for treatment of obesity,” was introduced in the 2025 session and referred to the Committee on Public Health, with no further action reported.¹⁴

1
Indiana Medicaid. Pharmacy Benefits
2
OptumRx / Indiana Medicaid. GLP-1 RA and GIP Combinations Prior Authorization Criteria
3
KFF. Medicaid Coverage of and Spending on GLP-1s
4
OptumRx / Indiana Medicaid. Indiana Medicaid Statewide Uniform Preferred Drug List
5
MHS Indiana. Pharmacy FAQs – Healthy Indiana Plan
6
MHS Indiana. MHS Preferred Drug List
7
CareSource. Indiana Medicaid Preferred Drug List
8
OptumRx / Indiana Medicaid. GLP-1 RA and GIP Combinations Prior Authorization Criteria – April 2025
9
Indiana Medicaid. Member Appeals
10
Novo Nordisk. What to Pay for Wegovy
11
NovoCare. Patient Assistance Program
12
CMS. Contract Year 2026 Policy and Technical Changes Final Rule Fact Sheet
13
KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid
14
LegiScan. Indiana HB1202 Fiscal Note